文献速递细菌感染、耐药与抗菌药物

一例产KPC肺炎克雷伯菌感染患者在头孢他啶/阿维巴坦治疗期间对亚胺培南/西司他丁/雷利巴坦耐药性的动态演变

Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

对同一患者在不同抗微生物治疗期间分离的产KPC肺炎克雷伯菌(KPC-Kp)菌株进行全基因组测序分析。治疗16天后出现头孢他啶/阿维巴坦耐药;耐药株携带blaKPC-53的Tn4401转座子从IncFII(K)质粒转移至43 kb IncX3质粒,亚胺培南/西司他丁/雷利巴坦耐药株则含两个Tn4401拷贝致blaKPC拷贝数增加,且为携带blaKPC-40和blaKPC-53等位基因的混合亚群。

要点

  • 治疗16天后出现头孢他啶/阿维巴坦耐药。
  • 亚胺培南/西司他丁/雷利巴坦耐药株含两个Tn4401拷贝,blaKPC拷贝数增加。
  • 耐药株为携带blaKPC-40和blaKPC-53等位基因的混合亚群。

核心结论

  • 结果显示,在接受不同头孢他啶/阿维巴坦方案治疗的KPC-Kp感染患者体内,发生了导致亚胺培南/雷利巴坦耐药的基因重排的体内演变。
  • 突变快速出现及其基因组的高适应性凸显了KPC-Kp的潜在威胁。

研究设计与样本

  • 对同一患者在不同时间及抗微生物治疗期间分离的KPC-Kp菌株进行全基因组测序分析。
  • 基因组组装采用Illumina iSeq 100和Minion Oxford Nanopore平台的混合方法。
  • 通过将Illumina reads比对至blaKPC进行亚群分析和等位基因频率测定。

主要发现

  • 在抗微生物治疗期间,治疗16天后观察到对头孢他啶/阿维巴坦的耐药。
  • 全基因组测序结果显示,所有KPC-Kp均表现为低SNP差异率,属于ST512,并具有相似的抗微生物耐药和外膜孔蛋白基因模式。
  • 遗传分析表明,第一株头孢他啶/阿维巴坦耐药KPC-Kp菌株的Tn4401转座子中携带blaKPC-53基因,该转座子从IncFII(K)质粒转移至一个43 kb的IncX3质粒。
  • 一株亚胺培南/西司他丁/雷利巴坦耐药菌株在IncFII(K)和IncX3质粒中携带两个Tn4401转座子拷贝,导致blaKPC拷贝数增加。
  • 频率分析表明,亚胺培南/西司他丁/雷利巴坦耐药KPC-Kp由携带blaKPC-40和blaKPC-53等位基因的混合亚群组成。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The novel carbapenem/β-lactamase inhibitor combination imipenem/cilastatin/relebactam has been developed for the treatment of infections due to carbapenemase-producing Enterobacteriaceae (CPE). Herein, we describe the in vivo evolution of imipenem/cilastatin/relebactam resistance in longitudinal intra-patient Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp) strains isolated from a patient following ceftazidime/avibactam-based treatments. METHODS: WGS analysis was performed on KPC-Kp strains isolated at different times and during antimicrobial treatments from the same patient. Genome assemblies were performed using a hybrid approach using Illumina iSeq 100 and Minion Oxford Nanopore platforms. Subpopulation analysis and allele frequency determination was performed by mapping Illumina reads to blaKPC. RESULTS: During antimicrobial treatment, resistance to ceftazidime/avibactam was observed following 16 days of antimicrobial therapy. WGS results showed that all KPC-Kp exhibited a low SNP rate of divergence, belonged to ST512 and shared similar antimicrobial resistance and porin gene patterns. Genetic analysis demonstrated that the first ceftazidime/avibactam-resistant KPC-Kp strain harboured a blaKPC-53 gene in a Tn4401 transposon moved from IncFII(K) to a 43 kb IncX3 plasmid, while a imipenem/cilastatin/relebactam-resistant strain exhibited two copies of the Tn4401 transposon in IncFII(K) and IncX3 plasmids, resulting in an increased blaKPC copy number. Of note, frequency analysis demonstrated that imipenem/cilastatin/relebactam-resistant KPC-Kp consisted of mixed subpopulations harbouring blaKPC-40 and blaKPC-53 alleles. CONCLUSIONS: Our results show the in vivo evolution of genetic rearrangement conferring resistance to imipenem/relebactam in a patient with KPC-Kp infection and treated with different ceftazidime/avibactam-based treatments. The rapid development of mutations and the high adaptability of its genome highlight the potential threat of KPC-Kp.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Gaibani P, Bovo F, Bussini L, et al. Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments. J Antimicrob Chemother. 2022. PMID: 35373297. doi:10.1093/jac/dkac100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。